SCHEMBL6668041

SCHEMBL6668041

COc1ccc(CNC(=O)c2ccc3c(c2)C(=O)C(Cc2cccc(Cl)c2)C(=O)N3)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.51
ALDH1A1 P00352 3/20 0.51
LMNA P02545 2/20 0.51
POLB P06746 1/20 0.51
GAA P10253 1/20 0.51
ROCK2 O75116 1/20 0.47
ROCK1 Q13464 1/20 0.47
DRD2 P14416 1/20 0.47
RXFP1 Q9HBX9 2/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
KMT2A Q03164 2/20 0.46
MAPK1 P28482 2/20 0.46
MMP13 P45452 1/20 0.44
MEN1 O00255 1/20 0.44
EPHX2 P34913 1/20 0.44
NR1H4 Q96RI1 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
TP53 P04637 1/20 0.44
MAPK10 P53779 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6678320 0.91 MAPT (0.55) MAPTALDH1A1LMNAPOLBGAA
SCHEMBL6668023 0.90 MAPT (0.55) MAPTALDH1A1LMNAPOLBGAA
SCHEMBL6678821 0.90 MAPT (0.53) MAPTALDH1A1LMNAPOLBGAA
SCHEMBL6664618 0.90 ALDH1A1 (0.53) MAPTALDH1A1LMNAPOLBGAA
SCHEMBL6682598 0.89 MAPT (0.51) MAPTALDH1A1LMNAPOLBGAA
SCHEMBL6679778 0.89 MAPT (0.47) MAPTLMNAPOLBRXFP1RAB9A
SCHEMBL6683152 0.88 MAPT (0.53) MAPTALDH1A1LMNAPOLBGAA
SCHEMBL6685985 0.87 MAPT (0.51) MAPTALDH1A1LMNAPOLBGAA
SCHEMBL6835304 0.82 ALDH1A1 (0.46) MAPTALDH1A1LMNAPOLBGAA
SCHEMBL6686372 0.82 ALDH1A1 (0.49) MAPTALDH1A1POLBROCK2ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040043985-A1 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors HICKS JAMES LESTER (US) 2004-03-04 US disclosed
WO-2004014388-A1 6,6-FUSED HETEROARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040043985-A1 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors MMP13, MMP26, MMP9 MAPT 2365/4885ALDH1A1 1202/4885LMNA 2566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.